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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER1547Vitamin D and Cardiovascular DiseaseCarl J. Lavie, John H. Lee, Richard V. Milani
Lavie and colleagues focus on the relationship between vitamin D and cardiovascular (CV)
risk factors and events, as well as the possibility that repleting vitamin D levels will improve
outcomes. The substantial evidence associating low vitamin D levels with adverse effects on
the CV system, including activation of the renin-angiotensin aldosterone system, insulin
resistance, and systemic inflammation, is reviewed. However, there is limited evidence that
vitamin D supplementation leads to a reduction in CV events, highlighting the need for
large, randomized, controlled trials to determine whether routine vitamin D assessment and
supplementation will improve CV outcomes.CLINICAL RESEARCH CLINICAL TRIAL
1557Carotid Stenting Results in Early Improvements in
Quality of Life Compared With Carotid EndarterectomyDavid J. Cohen, Joshua M. Stolker, Kaijun Wang, Elizabeth A. Magnuson, Wayne M. Clark,
Bart M. Demaerschalk, Albert D. Sam, Jr, James R. Elmore, Fred A. Weaver, Herbert D. Aronow,
Larry B. Goldstein, Gary S. Roubin, George Howard, Thomas G. Brott, on behalf of the
CREST Investigators
Cohen and colleagues compared health-related quality of life (HRQOL) in patients treated
with carotid artery stenting (CAS) or carotid endarterectomy in CREST (Carotid
Revascularization Endarterectomy versus Stenting Trial). This trial showed that there was no
significant difference in the primary composite endpoint between the 2 procedures, but in
rates of stroke and myocardial infarction. HRQOL was assessed using the Medical Outcomes
Study Short-Form 36. At both 2 weeks and 1 month, CAS patients had higher HRQOL.
However, by 1 year there were no differences in any HRQOL measure. These results show
that among patients undergoing carotid revascularization, CAS results in better HRQOL
during the early recovery period, but the differences are no longer present at 1 year.
Editorial Comment: Daniel B. Mark, Manesh R. Patel, Kevin J. Anstrom, p. 1566(continued on page A-00)
OCTOBER 4, 2011 (continued) A-22INTERVENTIONAL CARDIOLOGY1569Meta-Analysis Shows Lower Risk of Stent Thrombosis With EESUsman Baber, Roxana Mehran, Samin K. Sharma, Somjot Brar, Jennifer Yu, Jung-Won Suh, Hyo-Soo Kim,
Seung-Jung Park, Adnan Kastrati, Antoinette de Waha, Prakash Krishnan, Pedro Moreno, Joseph Sweeny,
Michael C. Kim, Javed Suleman, Robert Pyo, Jose Wiley, Jason Kovacic, Annapoorna S. Kini,
George D. Dangas
Compared to earlier drug-eluting stents (DES), the antiproliferative agent in the everolimus-
eluting stent (EES) is released from a thin biocompatible fluoropolymer on a low profile
flexible cobalt chromium metallic stent platform. Baber and colleagues performed a meta-
analysis of 13 randomized trials with over 17,000 subjects that randomized subjects to an
EES or another DES to compare the rates of stent thrombosis (ST). The rate of ST with
EES was reduced by almost 50%, with an absolute difference of 0.5%. There were also lower
rates of myocardial infarction and target vessel revascularization, but no significant difference
in cardiac mortality. This large meta-analysis is powered to detect differences in rates of
infrequent events and suggests that treating 200 patients with an EES rather than one of the
previous DES would prevent 1 case of ST.INTERVENTIONAL CARDIOLOGY
15781-Year Clinical and Imaging Outcomes With Second-Generation
Bioresorbable Everolimus-Eluting Vascular ScaffoldPatrick W. Serruys, Yoshinobu Onuma, Dariusz Dudek, Pieter C. Smits, Jacques Koolen, Bernard Chevalier,
Bernard de Bruyne, Leif Thuesen, Dougal McClean, Robert-Jan van Geuns, Stephan Windecker,
Robert Whitbourn, Ian Meredith, Cecile Dorange, Susan Veldhof, Karine Miquel Hebert,
Krishnankutty Sudhir, Hector M. Garcia-Garcia, John A. Ormiston
Serruys and colleagues used quantitative coronary angiography, intravascular ultrasound
(IVUS), virtual histology (VH), and optical coherence tomography (OCT) to study the
second generation ABSORB everolimus-eluting bioresorbable scaffold (Abbott Vascular,
Santa Clara, California). Overall, the scaffold area remained unchanged with IVUS as well as
with OCT, whereas VH radiofrequency backscattering and the echogenicity of the struts
showed reduction in the strut core area. OCT showed that 97% of the struts were covered at
follow-up, and malapposition was only detected in 4 scaffolds. These results at 1 year justify
the conduct of a larger, randomized trial to test the performance of the second-generation
ABSORB bioresorbable everolimus-eluting scaffold.
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rINTERVENTIONAL CARDIOLOGY1592600-mg Loading Dose of Clopidogrel Improves Outcomes in Primary PCI PatientsGiuseppe Patti, György Ba´rczi, Dejan Orlic, Fabio Mangiacapra, Giuseppe Colonna, Vincenzo Pasceri,
Emanuele Barbato, Béla Merkely, Istva´n Édes, Miodrag Ostojic,William Wijns, Germano Di Sciascio
The ARYMDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during
Angioplasty-Myocardial Infarction) trial randomized ST-segment elevation myocardial
infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) to
either a 600- or 300-mg clopidogrel loading dose before the procedure. Infarct size, measured
as the area under the curve for creatine kinase-myocardial band release, was significantly lower
in the 600-mg group. In the 600-mg arm, Thrombolysis In Myocardial Infarction flow grade
3 after PCI was less frequent, left ventricular ejection fraction at discharge was improved,
30-day major adverse cardiovascular events were lower, and bleeding/entry-site complications
were not increased. These results suggest that in STEMI patients, pre-treatment with a 600-
mg clopidogrel loading dose prior to primary PCI should be the standard of care.ACUTE MYOCARDIAL INFARCTION
1600Chronic Kidney Disease and Risk of Presenting With
Acute Myocardial Infarction Versus Stable Exertional AnginaAlan S. Go, Nisha Bansal, Malini Chandra, Phenius V. Lathon, Stephen P. Fortmann, Carlos Iribarren,
Chi-yuan Hsu, Mark A. Hlatky, for the ADVANCE Study Investigators
Reduced kidney function increases the risk of developing coronary heart disease (CHD),
but it is not known whether it also influences the acuity of clinical presentation. Go and
colleagues studied 803 adults with incident acute myocardial infarction and 419 adults with
incident stable exertional angina who had a baseline estimated glomerular filtration rate
(eGFR) 130 ml/min/1.73 m2. Mean eGFR was lower among subjects with acute
yocardial infarction, and there was a strong, graded, independent association between
aving reduced eGFR and presenting with acute myocardial infarction. These results suggest
hat chronic kidney disease may promote plaque instability and increase the risk of plaque
upture.CARDIAC IMAGING
1608Conformational Change in Coronary Artery Structure
Assessed in Patients With Vasospastic AnginaAtsushi Tanaka, Kenei Shimada, Guillermo J. Tearney, Hironori Kitabata, Haruyuki Taguchi, Shota Fukuda,
Manabu Kashiwagi, Takashi Kubo, Shigeho Takarada, Kumiko Hirata, Masato Mizukoshi,
Junichi Yoshikawa, Brett E. Bouma, Takashi Akasaka
Tanaka and colleagues investigated changes in the arterial structure of patients with
vasospastic angina using optical coherence tomography (OCT) during provocative testing.
Lesions that demonstrated spasm frequently showed an intimal bump, a projection into the
lumen that disappeared after nitroglycerine. During provocative testing, these bumps
demonstrated intimal gathering, which was defined as a folding/gathering of the intima,
resulting in multiple kinks in the luminal contour. These OCT data suggest that abnormal
medial contraction is already present even when the artery is at an asymptomatic state, and
when provoked, this medial constriction squeezes and folds the intima.(continued on page A-00)
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1614High Risk of Stroke Following a Successful Modified Maze Surgery
in Those Without Left Atrial Contractile FunctionJonathan Buber, David Luria, Leonid Sternik, Ehud Raanani, Micha S. Feinberg, Ilan Goldenberg,
Eyal Nof, Osnat Gurevitz, Michael Eldar, Michael Glikson, Rafael Kuperstein
The mechanical contraction of the left atrium (LA) may be modified after the Maze
procedure. Buber and colleagues studied risk factors for stroke in 150 patients who underwent
surgical radiofrequency and cryoablation Maze procedures and were in sustained sinus
rhythm. One-third of patients had no evidence of left atrial mechanical contraction (LAMC),
defined as no A-wave on echocardiographic mitral inflow, at 3 months following surgery.
Multivariate analysis showed that the lack of LAMC was associated with a 5-fold increase in
the risk of stroke.Editorial Comment: Shunichi Homma, Marco Di Tullio, p. 1622ABNORMALITIES OF THE LEFT ATRIUM1624Hiatal Hernias Can Compress the Left Atrium and Impair Exercise ToleranceChristopher Naoum, Gregory L. Falk, Austin C.C. Ng, Tony Lu, Lloyd Ridley, Alvin J. Ing,
Leonard Kritharides, John Yiannikas
Naoum and colleagues investigated the pathophysiology of exercise intolerance in patients
with large hiatal hernias (HHs). Thirty patients were prospectively evaluated with resting and
stress echocardiography, cardiac computed tomography (CT), and respiratory function testing
before and after HH repair. At baseline, exertional dyspnea was present in 83% of patients.
Moderate-to-severe left atrium compression was qualitatively present in 77% of patients on
CT. Post-operatively, New York Heart Association functional class and exercise capacity
improved significantly and resolution of cardiac compression was observed. This study links
exercise impairment and cardiac compression in patients with large HHs.Editorial Comment: Thomas H. Marwick, p. 1635
